Tech Company Financing Transactions
ORIG3N Funding Round
ORIG3N, operating out of Boston, secured $3.1 million in funding from Hatteras Venture Partners, Harris & Harris Group and KTB Ventures.
Transaction Overview
Company Name
Announced On
2/5/2015
Transaction Type
Venture Equity
Amount
$3,100,000
Round
Undisclosed
Investors
Hatteras Venture Partners (Lead Investor) (Clay Thorp)
Proceeds Purpose
The funding will be used to expand Life Capsule which provides everyone the opportunity to contribute to the advancement of medical research of rare genetic inherited diseases and neurodegenerative diseases such as Parkinson's, Alzheimer's, MS and ALS.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
27 Drydock Ave. 3rd Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Boston based ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based upon Nobel Prize winning technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robin Smith
Chief Medical Officer
Michael Fang
Chief Operating Officer
Kate Blanchard
VP - Marketing
Jish Mukerji
Browse more venture capital transactions:
Prev: 2/5/2015: Dering Hall venture capital transaction
Next: 2/5/2015: Ntoggle venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs